4-Substituted piperidine derivatives

a technology of substituted piperidine and derivatives, which is applied in the direction of drug compositions, antibacterial agents, immunological disorders, etc., can solve the problem that nerves in the cns have a very limited ability to repair and regrow after injury

Active Publication Date: 2005-12-08
BIOAXONE BIOSCI
View PDF18 Cites 99 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0033] U.S. Pat. Nos. 4,849,521, 4,584,303, 4,866,077, 4,933,353, and 6,169,097, the disclosure of each of which is hereby incorporated by reference in its entirety, disclose methods to prepare a number of piperidines with substituents attached to one or more of the ring c

Problems solved by technology

While many tissues such as muscle, skin, and liver have the ability to repair and regrow afte

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 4-Substituted piperidine derivatives
  • 4-Substituted piperidine derivatives
  • 4-Substituted piperidine derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

N-Benzyloxycarbonyl-4-oxopiperidine (E-1)

[0515] A stirred solution of 4-oxopiperidine hydrochloride monohydrate (1.0 g, 6.5 mmol) in dry dichloromethane (DCM, 40 mL) was cooled to 0° C., treated with diisopropylethylamine (3.40 mL, 19.5 mmol), stirred for five minutes, treated over 20 minutes with benzyl chloroformate (1.54 mL, 10.7 mmol) over 20 minutes, allowed to warm to room temperature and stirred for two hours. The mixture was partitioned between DCM (25 mL) and water (15 mL). The layers were separated and the aqueous phase was extracted with DCM (2×25 mL). The combined organic phases were washed with brine (1×15 mL), dried over Na2SO4 and evaporated to a residue that was purified by column chromatography using a gradient of 20 to 40% EtOAc in hexanes as eluant. Evaporation of the collected fractions gave carbamate E-1 (1.20 g, 85%) as a clear oil: HRMS calc'd for C13H15NO3 (M+): 233.1051, found: 233.1048; 1H NMR (CDCl3) δ 2.43 (s, 4H), 3.78 (d, 4H, J=5.96), 5.16 (s, 2H), 7.3...

example 2

N-Benzyloxycarbonyl-4-[(N″-(tert-butyloxycarbonyl)hydrazono]piperidine (E-2)

[0516] To a stirred solution of N-benzyloxycarbonyl-4-oxopiperidine (E-1, 1.02 g, 4.65 mmol) in dry toluene (25 mL), tert-butyl carbazate (616 mg, 4.65 mmol) was added at room temperature. The mixture was stirred for 5 minutes, allowed to stand at room temperature for 24 hours, treated with Na2SO4 (1 g), stirred at room temperature for 3 hours and filtered. The filtrate was evaporated to give quantitatively the hydrazone E-2 as an oil which was used in the next step without further purification: HRMS calcd for C18H26N3O4 [(MH)+]: 348.1923, found: 348.1935, 1H NMR (CDCl3) δ 1.48 (s, 9H), 2.35 (m, 2H), 2.51 (m, 2H), 3.62 (m, 4H), 5.13 (s, 2H), 7.33 (m, 5H), 7.77 (br s, 1H).

example 3

N-Benzyloxycarbonyl-4-[N″-(tert-butyloxycarbonyl)hydrazino]piperidine (E-3)

[0517] A stirred solution of N-benzyloxycarbonyl-4-[(N″-(tert-butyloxycarbonyl)hydrazono]piperidine (E-2, 1.56 g, 4.49 mmol) in dry tetrahydrofuran (THF, 7.5 mL) at room temperature was treated with sodium cyanoborohydride (353 mg, 5.61 mmol) followed by bromocresol green (2 mg). The mixture was stirred vigorously at room temperature, treated with a solution of p-toluenesulfonic acid (773 mg, 4.49 mmol) in dry THF (8 mL) over two hours in order to maintain a green colored mixture. The reaction was partitioned between EtOAc (25 mL) and brine (20 mL). The phases were separated and the aqueous phase was extracted with EtOAc (3×10 mL). The combined organic phases were washed with NaHCO3 sat. (2×15 mL) and brine (1×15 mL), dried over Na2SO4 and evaporated to a residue, that was suspended in dioxane (10 mL), treated slowly with aqueous sodium hydroxide (1 N, 3 mL), stirred for 5 minutes at room temperature and par...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Substituted piperidine compounds represented by the structure I are provided,
wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may inhibit intracellular Rho kinase enzyme found in nerve cells in mammals, and may find utility in repair of damaged nerves in the central and peripheral nervous system of such mammals. These compounds may induce the regeneration or growth of neurites in mammalian nerve cells and may thereby induce regeneration of damaged or diseased nerve tissue. These compounds also find additional utility as antagonists of the enzyme Rho kinase in treatment of disease states in which Rho kinase is implicated. Pharmaceutical compositions containing these substituted piperidine compounds may be useful to promote neurite growth and in the treatment of diseases in which Rho kinase inhibition is indicated.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Ser. No. 60 / 546,936, filed Feb. 24, 2004, the contents of which are incorporated by reference.FIELD OF THE INVENTION [0002] The present invention relates to substituted piperidine molecules or compounds which are inhibitors of Rho kinase, and in particular to substituted piperidine compounds which may be membrane permeable and that may promote neurite growth, and to pharmaceutical compositions comprising these compounds. The present invention also relates to the use of these compositions and compounds to repair damage to nerve cells and to components of nerve structures in the central nervous system and in the peripheral nervous system, to prevent ischemic cell death, and to treat various disease states wherein the treatment comprises inactivation or inhibition of Rho kinase. BACKGROUND OF THE INVENTION [0003] The central nervous system (CNS) is composed of the brain contained in the cranium, and th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/445A61K31/454A61K31/4545A61K31/4709A61K31/4725A61K31/52A61P25/00A61P35/00C07D211/56C07D211/58C07D211/60C07D211/72C07D211/74C07D211/96C07D401/06C07D401/12C07D401/14C07D403/12C07D471/04C07D473/00C07D473/14
CPCC07D211/58C07D211/72C07D211/74C07D401/06C07D403/12A61P1/04A61P11/06A61P15/06A61P15/08A61P15/10A61P19/10A61P25/00A61P25/16A61P25/28A61P27/02A61P27/06A61P29/00A61P31/04A61P31/18A61P35/00A61P37/00A61P37/06A61P43/00A61P9/00A61P9/10A61P9/12
Inventor MCKERRACHER, LISATHOUIN, ERYKLUBELL, WILLIAMSNOW, ROBERTGINGRAS, KARINE
Owner BIOAXONE BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap